PVLA

Palvella Therapeutics (PVLA)

About Palvella Therapeutics (PVLA)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Details

Daily high

$102.45

Daily low

$95.96

Price at open

$96.79

52 Week High

$112.00

52 Week Low

$11.17

Market cap

1.1B

Dividend yield

0.00%

Volume

295,291

Avg. volume

286,159

P/E ratio

-7.63

Palvella Therapeutics News